124 related articles for article (PubMed ID: 27127168)
1. Immunohistochemical Characterization of Histone Deacetylase as a Potential Prognostic Marker and Therapeutic Target in Endometrial Stromal Sarcoma.
Baek MH; Park JY; Rhim CC; Park Y; Kim KR; Kim JH; Nam JH
Anticancer Res; 2016 May; 36(5):2527-34. PubMed ID: 27127168
[TBL] [Abstract][Full Text] [Related]
2. Investigation of hormone receptor expression and its prognostic value in endometrial stromal sarcoma.
Park JY; Baek MH; Park Y; Kim YT; Nam JH
Virchows Arch; 2018 Jul; 473(1):61-69. PubMed ID: 29869299
[TBL] [Abstract][Full Text] [Related]
3. Effects of targeting endometrial stromal sarcoma cells via histone deacetylase and PI3K/AKT/mTOR signaling.
Quan P; Moinfar F; Kufferath I; Absenger M; Kueznik T; Denk H; Zatloukal K; Haybaeck J
Anticancer Res; 2014 Jun; 34(6):2883-97. PubMed ID: 24922651
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis for therapeutic targets and prognostic markers in low-grade endometrial stromal sarcoma.
Park JY; Kim KR; Nam JH
Int J Gynecol Cancer; 2013 Jan; 23(1):81-9. PubMed ID: 23221606
[TBL] [Abstract][Full Text] [Related]
5. Transition from low-grade endometrial stromal sarcoma to high-grade endometrial stromal sarcoma.
Ohta Y; Suzuki T; Omatsu M; Hamatani S; Shiokawa A; Kushima M; Ota H
Int J Gynecol Pathol; 2010 Jul; 29(4):374-7. PubMed ID: 20567152
[TBL] [Abstract][Full Text] [Related]
6. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression.
Geller MA; Argenta P; Bradley W; Dusenbery KE; Brooker D; Downs LS; Judson PL; Carson LF; Boente MP
Gynecol Oncol; 2004 Dec; 95(3):632-6. PubMed ID: 15581975
[TBL] [Abstract][Full Text] [Related]
7. Outcome and prognostic factors in endometrial stromal tumors: a Rare Cancer Network study.
Schick U; Bolukbasi Y; Thariat J; Abdah-Bortnyak R; Kuten A; Igdem S; Caglar H; Ozsaran Z; Lössl K; Schleicher U; Zwahlen D; Villette S; Vees H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e757-63. PubMed ID: 22300565
[TBL] [Abstract][Full Text] [Related]
8. Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells.
Hrzenjak A; Moinfar F; Kremser ML; Strohmeier B; Staber PB; Zatloukal K; Denk H
Mol Cancer Ther; 2006 Sep; 5(9):2203-10. PubMed ID: 16985053
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of endometrial stromal sarcoma and undifferentiated endometrial sarcoma as premises for new therapeutic strategies.
Hrzenjak A; Dieber-Rotheneder M; Moinfar F; Petru E; Zatloukal K
Cancer Lett; 2014 Nov; 354(1):21-7. PubMed ID: 25128649
[TBL] [Abstract][Full Text] [Related]
10. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway.
Hrzenjak A; Kremser ML; Strohmeier B; Moinfar F; Zatloukal K; Denk H
J Pathol; 2008 Dec; 216(4):495-504. PubMed ID: 18850582
[TBL] [Abstract][Full Text] [Related]
11. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients.
Bodner K; Bodner-Adler B; Obermair A; Windbichler G; Petru E; Mayerhofer S; Czerwenka K; Leodolter S; Kainz C; Mayerhofer K
Gynecol Oncol; 2001 May; 81(2):160-5. PubMed ID: 11330943
[TBL] [Abstract][Full Text] [Related]
12. Endometrial stromal sarcomas: immunoprofile with emphasis on HMB45 reactivity.
Albores-Saavedra J; Dorantes-Heredia R; Chablé-Montero F; Chanona-Vilchis J; Pérez-Montiel D; Lino-Silva LS; González-Romo MA; Ramírez-Jaramillo JM; Henson DE
Am J Clin Pathol; 2014 Jun; 141(6):850-5. PubMed ID: 24838330
[TBL] [Abstract][Full Text] [Related]
13. [Recent advances in pathology of endometrial stromal tumors].
Huang WT; Yang WT
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):752-4. PubMed ID: 17374263
[No Abstract] [Full Text] [Related]
14. Expression of androgen receptors in benign and malignant endometrial stromal neoplasms.
Moinfar F; Regitnig P; Tabrizi AD; Denk H; Tavassoli FA
Virchows Arch; 2004 May; 444(5):410-4. PubMed ID: 15007645
[TBL] [Abstract][Full Text] [Related]
15. Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Baek MH; Park JY; Rhim CC; Kim JH; Park Y; Kim KR; Nam JH
Gynecol Obstet Invest; 2017; 82(4):329-339. PubMed ID: 28125812
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma.
Cabrera S; Bebia V; Acosta U; Franco-Camps S; Mañalich L; García-Jiménez A; Gil-Moreno A
Clin Transl Oncol; 2021 Jun; 23(6):1210-1219. PubMed ID: 33210235
[TBL] [Abstract][Full Text] [Related]
17. Metastatic endometrial stromal sarcoma of the lung: importance of immunohistochemical staining, clinical history and imaging studies.
Mentrikoski MJ; Zhao C; Zhang J; Wang HL; McMahon LA; Yang Q; Li F; Xu H
Biotech Histochem; 2012 Jan; 87(1):35-9. PubMed ID: 21838613
[TBL] [Abstract][Full Text] [Related]
18. [Clinical review of 97 patients with endometrial stromal sarcoma].
Li N; Wu LY; Zhang HT; An JS; Li XG; Ma SK
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):115-9. PubMed ID: 18683750
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and molecular markers associated with prognosis and treatment effectiveness of endometrial stromal sarcoma: a retrospective study in China.
He L; Li JD; Xiong Y; Huang X; Huang L; Lin JX; Zhou Y; Zheng M
Arch Gynecol Obstet; 2014 Feb; 289(2):383-91. PubMed ID: 23959089
[TBL] [Abstract][Full Text] [Related]
20. Endometrial stromal sarcoma arising from endometriosis: a clinicopathological study and literature review.
Lan C; Huang X; Lin S; Cai M; Liu J
Gynecol Obstet Invest; 2012; 74(4):288-97. PubMed ID: 22986788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
